BTC Health Ltd (ASX: BTC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

BTC Health Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $16.92 million
P/E Ratio 4.13
Dividend Yield 0.00%
Shares Outstanding 325.32 million
Earnings per share 0.013
Dividend per share N/A
Year To Date Return -28.77%
Earnings Yield 24.23%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • BTC Health Ltd (ASX: BTC)
    Latest News

    a woman
    ⏸️ Investing

    6 listed funds with tax free capital gains and dividends

    Pooled Development Funds offer attractive tax treatment but come with high risk.

    Read more »

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    05 Jul 2011 $0.0280 0.00% Special Cash 15 Jul 2011
    03 Sep 2010 $0.0140 0.00% Final 13 Sep 2010

    BTC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About BTC Health Ltd

    BTC Health Ltd is a pooled development fund. The company is seeking new investment opportunities in entities operating in the biotechnology/life-science sectors. Its only operating segment is the making and managing of healthcare ventures.The company's products include Rythmic Infusion Pumps, Elasto-Q, ambIT, Infusion and Nerve Catheter Kits, Tiva, Rebellion - Bone Removal System, Ilumark, COLIBRI, ECMOLIFE, ECLS Heaters Coolers.

    BTC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    19 Jun 2025 $0.05 $0.00 0.00% 46,582 $0.05 $0.05 $0.05
    16 Jun 2025 $0.05 $0.00 0.00% 118,800 $0.05 $0.05 $0.05
    13 Jun 2025 $0.05 $0.00 0.00% 10,000 $0.05 $0.05 $0.05
    12 Jun 2025 $0.05 $0.00 0.00% 2,500 $0.05 $0.05 $0.05
    11 Jun 2025 $0.05 $0.00 0.00% 35,227 $0.05 $0.05 $0.05
    05 Jun 2025 $0.05 $0.00 0.00% 4,000 $0.05 $0.05 $0.05
    04 Jun 2025 $0.05 $0.00 0.00% 50,322 $0.05 $0.05 $0.05
    03 Jun 2025 $0.05 $0.00 0.00% 10,003 $0.05 $0.05 $0.05
    29 May 2025 $0.05 $0.00 0.00% 99,321 $0.05 $0.05 $0.05

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    19 Mar 2025 Richard Treagus Buy 118,546 $6,285
    On-market trade.
    27 Jun 2024 Richard Treagus Buy 185,515 $7,094
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Richard Spencer Treagus Executive ChairmanExecutive Director Aug 2014
    Dr Treagus has over 25 years of experience in all aspects of the international pharmaceutical and biotechnology industry.
    Ms Felicity McNeill Non-Executive Director Oct 2022
    Ms McNeill has over 25 years of experience across the public and private sector including almost 15 years in the regulatory and subsidy systems for medicines, vaccines, devices and diagnostics in Australia.
    Mr Martin Kahanovitz Non-Executive Director Jun 2025
    Mr. Kahanovitz is the Chief Financial Officer of the Kahma Healthcare Group. He also serves as Director forThe Biologicals and Vaccine Institute of Southern Africa (Pty) Ltd t/a Biovac and as Chairperson for the Finance and Risk Board Committee. Mr. Kahanovitz is a registered Director with nearly 30 years of professional experience in the biotechnology, pharmaceutical, and medical industries. He is a successful entrepreneur, demonstrated by his role as a key architect in establishing a major bio-pharmaceutical company connected to global vaccine players, creating a leading JSE-listed integrated healthcare company that was acquired by an international pharmaceutical firm, and forming a unique group of synergistic healthcare companies with a diverse range of interests.
    Mr Salesh Balak Chief Financial OfficerCompany Secretary Mar 2025
    -
    Salesh Balak Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 94,738,597 29.23%
    Mrs Karen Elizabeth Treagus 29,561,515 9.12%
    Sigma Company Limited 16,856,467 5.20%
    Namarong Investments Pty Ltd 15,000,000 4.63%
    Glk Medical Pty Ltd 14,092,318 4.35%
    Kingfisher Medical Pty Ltd 14,092,318 4.35%
    Tau Investments Australia Pty Ltd 14,092,318 4.35%
    Mr Thomas Christopher Fennell 8,682,787 2.68%
    Mr Campbell Dinwoodie Taylor 8,393,127 2.59%
    Sigma Company Limited i 8,143,533 2.51%
    Argus Nominees Pty Ltd 5,500,000 1.70%
    Mrs Susan Maree Whiting 5,300,000 1.64%
    Citicorp Nominees Pty Limited 4,543,617 1.40%
    Windarri Investments Pty Ltd 4,213,727 1.30%
    Abeille Investments Pty Limited 3,800,000 1.17%
    Mr Nicholas Dermott Mcdonald 3,644,239 1.12%
    Sigma Company Limited ii 3,627,553 1.12%
    Namarong Investments Pty Ltd i 3,125,000 0.96%
    Linwierik Investments Pty Ltd 2,600,000 0.80%
    Chanuk Nominees Pty Ltd 2,000,000 0.62%
    Pritdown Pty Ltd 2,000,000 0.62%

    Profile

    since

    Note